X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
once-daily atomoxetine (91) 91
humans (80) 80
attention deficit disorder with hyperactivity - drug therapy (73) 73
index medicus (65) 65
psychiatry (63) 63
deficit hyperactivity disorder (61) 61
atomoxetine hydrochloride (60) 60
male (58) 58
atomoxetine (57) 57
female (56) 56
child (54) 54
adhd (53) 53
double-blind (52) 52
adolescent (51) 51
propylamines - therapeutic use (47) 47
attention deficit hyperactivity disorder (46) 46
adrenergic uptake inhibitors - therapeutic use (45) 45
attention-deficit hyperactivity disorder (45) 45
attention-deficit/hyperactivity disorder (45) 45
methylphenidate (45) 45
children (43) 43
treatment outcome (39) 39
adolescents (37) 37
drug therapy (33) 33
pharmacology & pharmacy (33) 33
propylamines - adverse effects (31) 31
double-blind method (30) 30
pediatrics (30) 30
adrenergic uptake inhibitors - adverse effects (29) 29
adult (22) 22
open-label (21) 21
hyperactivity (19) 19
psychology, developmental (19) 19
attention deficit disorder with hyperactivity - psychology (17) 17
neurosciences (17) 17
clinical trials (16) 16
adrenergic uptake inhibitors - administration & dosage (15) 15
central nervous system stimulants - therapeutic use (15) 15
methylphenidate - therapeutic use (15) 15
placebo (15) 15
propylamines - administration & dosage (15) 15
psychiatric status rating scales (15) 15
adults (14) 14
clinical neurology (14) 14
efficacy (14) 14
research (14) 14
comorbidity (13) 13
teenagers (13) 13
care and treatment (12) 12
deficit/hyperactivity disorder (12) 12
drug administration schedule (12) 12
central nervous system stimulants - adverse effects (11) 11
children & youth (11) 11
oppositional defiant disorder (11) 11
oros methylphenidate (11) 11
placebo-controlled trial (11) 11
randomized controlled trials as topic (11) 11
time factors (11) 11
central nervous system stimulants - administration & dosage (10) 10
deficit-hyperactivity disorder (10) 10
dose-response relationship, drug (10) 10
middle aged (10) 10
quality-of-life (10) 10
attention deficit disorder with hyperactivity - physiopathology (9) 9
neuropsychological tests (9) 9
adrenergic uptake inhibitors - pharmacology (8) 8
analysis (8) 8
atomoxetine hydrochloride - therapeutic use (8) 8
attention deficit disorder with hyperactivity - diagnosis (8) 8
meta-analysis (8) 8
pediatric-patients (8) 8
propylamines - pharmacology (8) 8
psychopharmacology (8) 8
quality of life (8) 8
young adult (8) 8
young-adults (8) 8
attention - drug effects (7) 7
child & adolescent psychiatry (7) 7
deficit/hyperactivity-disorder (7) 7
executive function - drug effects (7) 7
hyperactivity disorder (7) 7
lisdexamfetamine dimesylate (7) 7
methylphenidate - administration & dosage (7) 7
original articles (7) 7
patient outcomes (7) 7
pharmacotherapy (7) 7
child, preschool (6) 6
clinical trials as topic (6) 6
comparative analysis (6) 6
health aspects (6) 6
methylphenidate - adverse effects (6) 6
pharmacology (6) 6
prefrontal cortex (6) 6
review (6) 6
safety (6) 6
symptoms (6) 6
trial (6) 6
youth (6) 6
abridged index medicus (5) 5
adrenergic uptake inhibitors - pharmacokinetics (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Child Psychology and Psychiatry, ISSN 0021-9630, 01/2015, Volume 56, Issue 1, pp. 40 - 48
Background This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in... 
methylphenidate | attention | Attention‐deficit/hyperactivity disorder | vigilance | atomoxetine | Attention-deficit/hyperactivity disorder | ADHD | hyperactivity disorder | PSYCHIATRY | DEFICIT HYPERACTIVITY DISORDER | PSYCHOLOGY, DEVELOPMENTAL | ONCE-DAILY ATOMOXETINE | OPEN-LABEL | PREFRONTAL CORTEX | PSYCHOLOGY | CHILDREN | Attention-deficit | FUNCTIONAL MAGNETIC-RESONANCE | DOPAMINE | CONTINUOUS PERFORMANCE-TEST | STIMULANTS | Methylphenidate - administration & dosage | Central Nervous System Stimulants - pharmacology | Double-Blind Method | Humans | Male | Methylphenidate - pharmacology | Treatment Outcome | Psychomotor Performance - drug effects | Attention Deficit Disorder with Hyperactivity - drug therapy | Cross-Over Studies | Propylamines - administration & dosage | Adolescent | Atomoxetine Hydrochloride | Adrenergic Uptake Inhibitors - administration & dosage | Attention - drug effects | Adrenergic Uptake Inhibitors - pharmacology | Female | Propylamines - pharmacology | Central Nervous System Stimulants - administration & dosage | Child | Executive Function - drug effects | Inhibition (Psychology) | Psychological aspects | Care and treatment | Attention-deficit hyperactivity disorder | Youth | Dosage and administration | Teenagers | Comparative analysis | Methylphenidate hydrochloride | Methylphenidate | Risk factors | Psychotropic drugs | Attention Deficit Hyperactivity Disorder | Child & adolescent psychiatry | Vigilance | Atomoxetine | Hyperactivity Disorder | Attention | Attention-Deficit
Journal Article
Journal of the American Academy of Child & Adolescent Psychiatry, ISSN 0890-8567, 2008, Volume 47, Issue 2, pp. 209 - 218
Journal Article
European Child and Adolescent Psychiatry, ISSN 1018-8827, 12/2009, Volume 18, Issue 12, pp. 725 - 735
This 10-week study assessed the efficacy of atomoxetine in combination with psychoeducation compared to placebo and psychoeducation in the improvement of... 
ADHD | Broader efficacy | CHIP-CE | Atomoxetine | Quality of life | PSYCHIATRY | DEFICIT HYPERACTIVITY DISORDER | PSYCHOLOGY, DEVELOPMENTAL | ONCE-DAILY ATOMOXETINE | RELIABILITY | FTF 5 | PRESCHOOLERS | PEDIATRICS | QUALITY-OF-LIFE | PARENT REPORT FORM | QUESTIONNAIRE | VALIDITY | Humans | Cost of Illness | Male | Attention Deficit and Disruptive Behavior Disorders - diagnosis | Attention Deficit and Disruptive Behavior Disorders - drug therapy | Sweden | Education | Family Conflict - psychology | Atomoxetine Hydrochloride | Female | Quality of Life - psychology | Achievement | Attention Deficit and Disruptive Behavior Disorders - psychology | Child | Adrenergic Uptake Inhibitors - adverse effects | Adrenergic Uptake Inhibitors - therapeutic use | Double-Blind Method | Adaptation, Psychological - drug effects | Caregivers - psychology | Combined Modality Therapy | Attention Deficit Disorder with Hyperactivity - drug therapy | Parenting - psychology | Propylamines - therapeutic use | Self Concept | Harm Reduction | Attention Deficit Disorder with Hyperactivity - psychology | Child Rearing | Propylamines - adverse effects | Medicine, Experimental | Medical research | Neurosciences | Attention-deficit hyperactivity disorder | Clinical trials | Teenagers | Attention Deficit Hyperactivity Disorder | Children & youth | Index Medicus | Original Contribution | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Journal of the American Academy of Child & Adolescent Psychiatry, ISSN 0890-8567, 2012, Volume 51, Issue 7, pp. 733 - 741
Objective The efficacy of atomoxetine as treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in patients with autism spectrum disorder... 
Pediatrics | Psychiatry | ADHD | ASD | placebo-controlled | atomoxetine | TEACHER REPORTS | PSYCHIATRY | DEFICIT HYPERACTIVITY DISORDER | PSYCHOLOGY, DEVELOPMENTAL | ONCE-DAILY ATOMOXETINE | RISPERIDONE | PERVASIVE DEVELOPMENTAL DISORDERS | TRIAL | ADOLESCENTS | PARENT | METHYLPHENIDATE | PEDIATRICS | Autism | Outcomes of Treatment | Attention Deficit Hyperactivity Disorder | Age Differences | Teacher Evaluation | Disabilities | Children | Adolescents | Patients | Rating Scales | Drug Use | Adrenergic Uptake Inhibitors - adverse effects | Adrenergic Uptake Inhibitors - therapeutic use | Double-Blind Method | Follow-Up Studies | Comorbidity | Humans | Male | Psychometrics | Attention Deficit Disorder with Hyperactivity - drug therapy | Child Development Disorders, Pervasive - drug therapy | Personality Assessment - statistics & numerical data | Propylamines - therapeutic use | Child Development Disorders, Pervasive - psychology | Adolescent | Atomoxetine Hydrochloride | Child Development Disorders, Pervasive - diagnosis | Attention Deficit Disorder with Hyperactivity - psychology | Female | Attention Deficit Disorder with Hyperactivity - diagnosis | Child | Propylamines - adverse effects | Care and treatment | Research | Attention-deficit hyperactivity disorder | Pervasive developmental disorders | Clinical trials | Drug therapy | Pharmaceuticals | Child & adolescent psychiatry
Journal Article
Journal Article
Psychological Medicine, ISSN 0033-2917, 11/2016, Volume 46, Issue 15, pp. 3173 - 3185
Background. Methylphenidate and atomoxetine are commonly prescribed for treating attention deficit hyperactivity disorder (ADHD). However, their therapeutic... 
resting brain imaging | methylphenidate | Atomoxetine | attention deficit hyperactivity disorder | fractional amplitude of low-frequency fluctuations | ADHD | RESTING-STATE FMRI | PSYCHIATRY | ONCE-DAILY ATOMOXETINE | OPEN-LABEL | PSYCHOLOGY, CLINICAL | PSYCHOLOGY | DEFICIT/HYPERACTIVITY DISORDER | BOYS | MOTOR CORTEX | HEALTHY-VOLUNTEERS | WORKING-MEMORY | EXECUTIVE FUNCTIONS | Attention Deficit Disorder with Hyperactivity - physiopathology | Brain - diagnostic imaging | Adrenergic Uptake Inhibitors - therapeutic use | Atomoxetine Hydrochloride - therapeutic use | Brain - physiopathology | Frontal Lobe - physiopathology | Humans | Somatosensory Cortex - physiopathology | Dopamine Uptake Inhibitors - therapeutic use | Male | Somatosensory Cortex - diagnostic imaging | Treatment Outcome | Occipital Lobe - physiopathology | Attention Deficit Disorder with Hyperactivity - drug therapy | Parietal Lobe - physiopathology | Frontal Lobe - diagnostic imaging | Magnetic Resonance Imaging | Functional Neuroimaging | Adolescent | Methylphenidate - therapeutic use | Parietal Lobe - diagnostic imaging | Female | Child | Occipital Lobe - diagnostic imaging | Regional variations | Neuroimaging | Nuclear magnetic resonance--NMR | Childrens health | Mental health | Cognitive ability | Resting | Superior temporal gyrus | Brain activity | Cortex (parietal) | Functional magnetic resonance imaging | Movement time | Children | Neuropsychology | Prescribed | Fluctuations | Impulsivity | Attention deficit hyperactivity disorder | Brain mapping | Reaction time task | Temporal gyrus | Magnetic resonance imaging | Impulsive behavior | Methylphenidate
Journal Article